136 related articles for article (PubMed ID: 32803073)
1. Site-Specific Lipidation of a Small-Sized Protein Binder Enhances the Antitumor Activity through Extended Blood Half-Life.
Kim TY; Nam YR; Park JH; Lee DE; Kim HS
ACS Omega; 2020 Aug; 5(31):19778-19784. PubMed ID: 32803073
[TBL] [Abstract][Full Text] [Related]
2. Prolonged half-life of small-sized therapeutic protein using serum albumin-specific protein binder.
Kim TY; Park JH; Shim HE; Choi DS; Lee DE; Song JJ; Kim HS
J Control Release; 2019 Dec; 315():31-39. PubMed ID: 31654685
[TBL] [Abstract][Full Text] [Related]
3. A dimeric form of a small-sized protein binder exhibits enhanced anti-tumor activity through prolonged blood circulation.
Kim TY; Seo HD; Lee JJ; Kang JA; Kim WS; Kim HM; Song HY; Park JM; Lee DE; Kim HS
J Control Release; 2018 Jun; 279():282-291. PubMed ID: 29698702
[TBL] [Abstract][Full Text] [Related]
4. The molecular basis for the prolonged blood circulation of lipidated incretin peptides: Peptide oligomerization or binding to serum albumin?
Wang Y; Lomakin A; Kanai S; Alex R; Belli S; Donzelli M; Benedek GB
J Control Release; 2016 Nov; 241():25-33. PubMed ID: 27578099
[TBL] [Abstract][Full Text] [Related]
5. Orthogonal assembly of a designed ankyrin repeat protein-cytotoxin conjugate with a clickable serum albumin module for half-life extension.
Simon M; Frey R; Zangemeister-Wittke U; Plückthun A
Bioconjug Chem; 2013 Nov; 24(11):1955-66. PubMed ID: 24168270
[TBL] [Abstract][Full Text] [Related]
6. Fusion to an albumin-binding domain with a high affinity for albumin extends the circulatory half-life and enhances the in vivo antitumor effects of human TRAIL.
Li R; Yang H; Jia D; Nie Q; Cai H; Fan Q; Wan L; Li L; Lu X
J Control Release; 2016 Apr; 228():96-106. PubMed ID: 26951928
[TBL] [Abstract][Full Text] [Related]
7. Genetically Encoding a Lipidated Amino Acid for Extension of Protein Half-Life in vivo.
Fu C; Chen Q; Zheng F; Yang L; Li H; Zhao Q; Wang X; Wang L; Wang Q
Angew Chem Int Ed Engl; 2019 Jan; 58(5):1392-1396. PubMed ID: 30474173
[TBL] [Abstract][Full Text] [Related]
8. Generation of therapeutic protein variants with the human serum albumin binding capacity via site-specific fatty acid conjugation.
Cho J; Lim SI; Yang BS; Hahn YS; Kwon I
Sci Rep; 2017 Dec; 7(1):18041. PubMed ID: 29269881
[TBL] [Abstract][Full Text] [Related]
9. The Minimal Effect of Linker Length for Fatty Acid Conjugation to a Small Protein on the Serum Half-Life Extension.
Cho J; Park J; Tae G; Jin MS; Kwon I
Biomedicines; 2020 Apr; 8(5):. PubMed ID: 32357510
[TBL] [Abstract][Full Text] [Related]
10. Site-Specific Albumination as an Alternative to PEGylation for the Enhanced Serum Half-Life in Vivo.
Yang B; Lim SI; Kim JC; Tae G; Kwon I
Biomacromolecules; 2016 May; 17(5):1811-7. PubMed ID: 27050863
[TBL] [Abstract][Full Text] [Related]
11. Cellular recycling-driven in vivo half-life extension using recombinant albumin fusions tuned for neonatal Fc receptor (FcRn) engagement.
Larsen MT; Rawsthorne H; Schelde KK; Dagnæs-Hansen F; Cameron J; Howard KA
J Control Release; 2018 Oct; 287():132-141. PubMed ID: 30016735
[TBL] [Abstract][Full Text] [Related]
12. Endogenous IgG-based affinity-controlled release of TRAIL exerts superior antitumor effects.
Yang H; Feng Y; Cai H; Jia D; Li H; Tao Z; Zhong Y; Li Z; Shi Q; Wan L; Li L; Lu X
Theranostics; 2018; 8(9):2459-2476. PubMed ID: 29721092
[TBL] [Abstract][Full Text] [Related]
13. Site-specific albumination of a therapeutic protein with multi-subunit to prolong activity in vivo.
Lim SI; Hahn YS; Kwon I
J Control Release; 2015 Jun; 207():93-100. PubMed ID: 25862515
[TBL] [Abstract][Full Text] [Related]
14. Recombinant Peptide Production Platform Coupled with Site-Specific Albumin Conjugation Enables a Convenient Production of Long-Acting Therapeutic Peptide.
Bak M; Park J; Min K; Cho J; Seong J; Hahn YS; Tae G; Kwon I
Pharmaceutics; 2020 Apr; 12(4):. PubMed ID: 32316169
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and stability of the ch14.18-interleukin-2 fusion protein in mice.
Kendra K; Gan J; Ricci M; Surfus J; Shaker A; Super M; Frost JD; Rakhmilevich A; Hank JA; Gillies SD; Sondel PM
Cancer Immunol Immunother; 1999 Aug; 48(5):219-29. PubMed ID: 10478638
[TBL] [Abstract][Full Text] [Related]
16. A paclitaxel prodrug with bifunctional folate and albumin binding moieties for both passive and active targeted cancer therapy.
Shan L; Zhuo X; Zhang F; Dai Y; Zhu G; Yung BC; Fan W; Zhai K; Jacobson O; Kiesewetter DO; Ma Y; Gao G; Chen X
Theranostics; 2018; 8(7):2018-2030. PubMed ID: 29556370
[TBL] [Abstract][Full Text] [Related]
17. An Albumin Sandwich Enhances in Vivo Circulation and Stability of Metabolically Labile Peptides.
Tian R; Zhu S; Zeng Q; Lang L; Ma Y; Kiesewetter DO; Liu Y; Fu X; Lau J; Zhu G; Jacobson O; Wang Z; Dai Y; Yu G; Brooks BR; Liu G; Niu G; Chen X
Bioconjug Chem; 2019 Jun; 30(6):1711-1723. PubMed ID: 31082207
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and in vitro and in vivo anti-tumor response of an interleukin-2-human serum albumin fusion protein in mice.
Melder RJ; Osborn BL; Riccobene T; Kanakaraj P; Wei P; Chen G; Stolow D; Halpern WG; Migone TS; Wang Q; Grzegorzewski KJ; Gallant G
Cancer Immunol Immunother; 2005 Jun; 54(6):535-47. PubMed ID: 15592670
[TBL] [Abstract][Full Text] [Related]
19. Conjugation to 10 kDa Linear PEG Extends Serum Half-Life and Preserves the Receptor-Binding Ability of mmTRAIL with Minimal Stimulation of PEG-Specific Antibodies.
Nie Q; Jia D; Yang H; Feng Y; Fan Q; Shi Q; Wan L; Lu X
Mol Pharm; 2017 Feb; 14(2):502-512. PubMed ID: 28029256
[TBL] [Abstract][Full Text] [Related]
20. Enhancing Treatment Efficacy of
Kuo HT; Merkens H; Zhang Z; Uribe CF; Lau J; Zhang C; Colpo N; Lin KS; Bénard F
Mol Pharm; 2018 Nov; 15(11):5183-5191. PubMed ID: 30251544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
